Page last updated: 2024-09-05

sorafenib and MEA 2b

sorafenib has been researched along with MEA 2b in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S1
Cagan, RL; Dar, AC; Das, TK; Shokat, KM1

Other Studies

2 other study(ies) available for sorafenib and MEA 2b

ArticleYear
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
    Pediatric blood & cancer, 2012, Volume: 58, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms

2012
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
    Nature, 2012, Jun-06, Volume: 486, Issue:7401

    Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays

2012